Food and Drug Administration (FDA) in 2017 for the treatment of type 2 diabetes to improve blood sugar control and reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease [1]
They found that for FDA approved GLP-1s for weight loss, liraglutide (Saxenda) and semaglutide (Wegovy), the percent of side effects reported was as follows: Nausea: 42.2% Diarrhea: 21.9% Vomiting: also 21.9% Constipation: 8.4% They report that although the incidence of side effects were similar among medications, semaglutide had the greatest risk of nausea, diarrhea, and vomiting, whereas liraglutide had the greatest risk of upper abdominal pain
The objective of this review is to summarize the genetic mechanisms, diagnosis and treatment progress of GDH-HI
If youre considering medical weight loss medications, continue reading to discover the critical components of Semaglutide/GLP-1 vs
Used judiciously, it can restore a sense of vitality and intimacy for men and their partners
What is the optimal time of day to take atomoxetine (Strattera)?
